Dr. Evelyn Reed, a rheumatologist practicing in suburban Atlanta, faced a familiar dilemma in late 2024: escalating costs for a critical biologic medication her patient, Mr. Arthur Jenkins, needed. Mr. Jenkins, a retired schoolteacher on a fixed income, relied on this drug to manage severe rheumatoid arthritis. His out-of-pocket expenses had nearly doubled in two years, despite the manufacturer claiming participation in various government initiatives to lower drug prices. This scenario, common across the United States, throws a harsh spotlight on the complexities of pharma pricing, particularly the promise and ultimate failure of Trump’s Most Favored Nation (MFN) model.
Key Takeaways
- The Trump administration’s Most Favored Nation (MFN) drug pricing model, implemented via executive order in 2020, aimed to lower US drug costs by tying them to prices paid in other developed countries.
- The MFN model faced immediate legal challenges and never fully took effect, in the end being rescinded in 2021 before significant implementation.
- Critics argued the MFN model was legally tenuous and could have unintended consequences, including reduced pharmaceutical innovation and limited drug availability.
- Current efforts to control drug costs, such as the Inflation Reduction Act’s negotiation provisions, represent a different approach to federal intervention in pharma pricing.
The concept of a Most Favored Nation (MFN) drug pricing model emerged prominently during the Trump administration, presented as a way to rein in the exorbitant costs Americans pay for prescription drugs. The core idea seemed simple: if other wealthy nations paid less for the same medications, why shouldn’t the U.S.? The executive order, signed in September 2020, sought to link Medicare Part B drug prices to the lowest prices paid for those drugs in a set of economically comparable countries, including Canada, France, Germany, and the United Kingdom. This wasn’t just a tweak. It was a fundamental shift, attempting to use international price controls to benefit American consumers.
Dr. Reed recalled reading the headlines at the time, a mix of optimism and skepticism. “We heard a lot about it,” she explained during a recent interview, “and I remember hoping it would make a difference for patients like Arthur. His medication is effective, life-changing even, but the cost burden is immense. He’s constantly worried about affording it.” The promise of MFN was indeed significant. Advocates argued it would force pharmaceutical companies to accept lower prices in the US, similar to what they negotiated with national healthcare systems abroad. The Centers for Medicare & Medicaid Services (CMS) even released an interim final rule to begin implementing the model, targeting 50 high-cost Medicare Part B drugs.
However, the MFN model, despite its bold ambition, proved to be more of a mirage than a concrete solution. Pharmaceutical companies and industry groups immediately challenged the executive order in court. Organizations like the Pharmaceutical Research and Manufacturers of America (PhRMA) argued that the policy was an overreach of executive authority, threatening innovation and potentially limiting patient access to new treatments. According to a Reuters report from December 2020, multiple federal judges issued injunctions, effectively blocking the implementation of the MFN rule. These legal battles highlighted the deep divisions and powerful lobbying efforts surrounding drug pricing reform.
The legal challenges were multifaceted. Manufacturers claimed the MFN model would force them to sell drugs below their cost of production, stifling research and development. They also argued it violated due process, as the government was attempting to set prices without adequate negotiation or consideration of the US market’s unique dynamics. This isn’t just about profits. Pharmaceutical companies invest billions in drug discovery, and they depend on higher prices in certain markets to recoup those investments. It’s a complex equation, and any sudden, imposed price reduction carries significant implications for future innovation pipelines. “The industry’s argument was always about the ‘cold reality’ of drug development,” noted Dr. Reed. “They spend years and fortunes on a single drug, and they expect a return. But where does that leave the patient who needs it?”
When the Biden administration took office in January 2021, the MFN executive order was quickly rescinded. The legal morass and the change in political priorities meant the model never truly saw the light of day. For patients like Mr. Jenkins, the brief glimmer of hope faded. His rheumatology appointments continued to involve discussions about formulary changes, patient assistance programs, and the ever-present anxiety of drug affordability. “It felt like a lot of talk, a lot of promises, but no real change for us,” Mr. Jenkins commented recently, his voice tinged with resignation.
The failure of the MFN model wasn’t just a political footnote. It underscored the deep difficulties in implementing sweeping drug price controls in the US. Unlike countries with centralized healthcare systems that can negotiate prices directly with pharmaceutical companies, the fragmented US system presents a formidable challenge. The MFN approach, while conceptually appealing for its simplicity, bypassed the established mechanisms and faced immediate, well-resourced opposition. It also raised legitimate questions about its potential long-term impact. Would it have led to drug shortages? Would pharmaceutical companies simply choose not to launch new products in the US if prices were dictated by other nations? These were significant concerns, even if they were often overshadowed by the immediate desire for lower costs.
The debate around pharma pricing didn’t end with the MFN model’s demise. Instead, it evolved. The Inflation Reduction Act (IRA) of 2022 introduced a different strategy: direct negotiation of drug prices for Medicare. This landmark legislation helps Medicare to negotiate prices for certain high-cost drugs, starting with a small number of medications and expanding over time. While distinct from the MFN model, the IRA also represents a significant federal intervention into drug pricing. As of 2026, the first negotiated prices under the IRA are beginning to take effect for a select group of drugs, offering a new test case for government-led price reduction efforts. According to reporting from the Associated Press, CMS announced the first ten drugs selected for negotiation in late 2023, with the negotiated prices expected to be published in late 2024 and effective in 2026.
Dr. Reed sees the IRA as a more structured, albeit slower, approach. “It’s not a silver bullet, but it’s a step,” she observed. “Unlike MFN, which felt like a blunt instrument, the IRA involves a negotiation process. It’s still early, but any mechanism that brings down costs for patients without jeopardizing access or innovation is something we need to explore thoroughly.” Her experience with Mr. Jenkins highlights the urgent need for effective solutions. While Mr. Jenkins’ specific biologic wasn’t among the initial drugs selected for IRA negotiation, the broader impact of such policies could eventually trickle down to his situation. The challenge remains to balance affordability with the pharmaceutical industry’s need to fund research and development for new treatments, a tension that the MFN model failed to resolve.
The MFN “mirage” is a powerful reminder: complex problems rarely have simple, quick fixes. While the intention to lower drug prices for Americans was clear, the execution and legal viability of the MFN model proved insurmountable. The pharmaceutical pricing debate continues, with legislative efforts like the IRA charting a different course, but the underlying goal remains the same: ensuring essential medications are accessible and affordable for everyone who needs them.
Understanding the intricacies of drug pricing mechanisms, from the MFN model’s brief appearance to current legislative efforts, is essential for patients, providers, and policymakers. The path to affordable medications is long and arduous, requiring persistent engagement and a willingness to adapt strategies based on real-world outcomes and legal realities.
What was the core idea behind Trump’s Most Favored Nation (MFN) drug pricing model?
The MFN model aimed to lower prescription drug prices in the United States by pegging them to the lowest prices paid for those same drugs in a selection of other wealthy, developed countries.
Why did the MFN model in the end fail to be implemented?
The MFN model faced immediate and significant legal challenges from pharmaceutical companies and industry groups, resulting in federal court injunctions that blocked its implementation. It was subsequently rescinded by the Biden administration in 2021.
Which government agency was tasked with implementing the MFN drug pricing model?
The Centers for Medicare & Medicaid Services (CMS) was responsible for developing and implementing the interim final rule for the MFN model, which targeted Medicare Part B drugs.
How does the Inflation Reduction Act’s approach to drug pricing differ from the MFN model?
Unlike the MFN model’s direct price linkage, the Inflation Reduction Act (IRA) helps Medicare to directly negotiate drug prices with pharmaceutical manufacturers for a select number of high-cost medications, a process that began with the first ten drugs selected in 2023.
What were some of the key arguments against the MFN drug pricing model?
Opponents argued that the MFN model was an executive overreach, could stifle pharmaceutical innovation by reducing revenue for research and development, and might lead to drug shortages or reduced availability of new treatments in the US market.
